Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Dificlir
(Finland) [Available]Synonyms :
fidaxomicin
Class :
Antibiotics and macrolide
Brand Name :
Dificlir
(Finland) [Available]Synonyms :
fidaxomicin
Class :
Antibiotics and macrolide
Dosage forms & Strengths
Tablet, Oral:
200 mg
Suspension reconstituted, Oral:
40 mg/ml
Initial infection:
200 mg orally twice a day for 10 days
Recurrent infection:
200 mg orally twice a day for 5 days followed by 200 mg once every other day for 20 days
No dosage adjustment was described for renal/hepatic impairment
Dosage forms & Strengths
Tablet, Oral:
200 mg
Suspension reconstituted, Oral:
40 mg/ml
For Infants >6 months, children and adolescents:
4 to <7 kg:
80 mg oral suspension twice a day for 10 days
7 to <9 kg:
120 mg oral suspension twice a day for 10 days
9 to 12.5 kg:
160 mg oral suspension twice a day for 10 days
>12.5 kg:
200 mg oral suspension twice a day for 10 days
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
antibiotics may reduce the therapeutic efficacy of the cholera vaccine
macrolide antibiotics may reduce the plasma concentration of mizolastine.
antibiotics may reduce the therapeutic efficacy of sodium picosulfate
antibiotics may reduce the therapeutic efficacy of the typhoid vaccine
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the levels of serum concentration of cardiac glycosides
may increase the levels of serum concentration of cardiac glycosides
may increase the levels of serum concentration of cardiac glycosides
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect of antibiotics
may reduce the therapeutic effect of typhoid Vaccine
they increase the concentration of rilpivirine
The RNA polymerase is a vital bacterial enzyme that promotes several bacterial enzymatic activities vital to bacterial viability, controls gene expression, and catalyses nucleic acid interactions.
The active site of the core RNA polymerase is located within a complex of various subunits.
The core RNA polymerase’s active site attaches itself to a promoter-specificity σ initiation factor, which finds and attaches to a promoter region of the DNA to start bacterial transcription.
Inhibiting messenger RNA production and preventing the early separation of DNA strands during transcription, fidaxomicin binds to the DNA template-RNA polymerase complex.
Frequency defined:
>10%
Nausea (11%)
Fever (13%)
1%-10%:
Pruritis (5%)
Skin rash (2%)
Urticaria (5%)
Decreased serum bicarbonate (2%)
Metabolic acidosis (2%)
Abdominal distention (2%)
Diarrhea (7%)
Vomiting (7%)
Anemia (2%)
Neutropenia (2%)
Postmarketing:
Hepatotoxicity
Anaphylaxis
None
Contraindication:
Hypersensitivity
Caution:
Acute hypersensitivity reactions
Use in the absence of a confirmed or highly suspected C difficile infection is unlikely to help the patient and raises the possibility of drug-resistant bacteria growing.
Caution in patients with severe allergy to macrolide antibiotics.
Pregnancy consideration: Limited systemic absorption may reduce the potential risk for major birth defects, miscarriage, and fetal outcomes.
Lactation: No data available regarding the excretion of fidaxomicin in breast milk.
Pregnancy category:
Fidaxomicin shows strong bactericidal action against C. difficile and a narrow-spectrum antibacterial profile.
In vitro, the minimum inhibitory concentration of fidaxomicin against C. difficile for 90% of organisms varied between 0.0078 and 2 μg/mL.
Fidaxomicin cross-resistance was not observed in C. difficile isolates that are resistant to rifamycins or other antibiotic classes.
Oral Suspension Preparation:
To make sure there is no caking, and the grains are moving freely, shake the glass bottle. Fill a glass bottle with 130 mL of pure water, then screw on the cap.
For a minimum of two minutes, hold the bottle horizontally and shake it briskly.
Shake for a further thirty seconds after the homogenous suspension has been visually verified.
Wait a minute for the bottle to stand.
Oral suspension is white to yellowish white once it has been reconstituted.
For oral administration take dose with or without food.
Fifteen minutes prior to administration, take the bottle out of the fridge. Shake well until suspension is uniformly thick.
Using an oral dosage syringe, administer orally with or without meals after removing the cap. Replace the cap and keep it chilled in between doses.
Patient information leaflet
Generic Name: fidaxomicin
Why do we use fidaxomicin?
Fidaxomicin is indicated in the treatment of Clostridioides difficile-associated diarrhea.
Fidaxomicin and other antimicrobial drugs should only be administered in patients who have a confirmed or highly suspected C. difficile infection to minimize the formation of drug-resistant bacteria and to optimize their therapeutic efficacy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
